Arrayit Corporation Announces the Product Launch of OvaDx(R), the Market's First Pre-Symptomatic Screening Test for Ovarian Cancer
Share This Story
Company to Offer 1,000 Tests at the Annual Meeting of the American Association for Cancer Research
SUNNYVALE, Calif., April 1, 2011 (GLOBE NEWSWIRE) -- Arrayit Corporation announces today the product launch of OvaDx®, the market's first Pre-Symptomatic Screening Test for Ovarian Cancer. The company is offering the first 1,000 tests to attendees of the 102nd annual meeting of the American Association for Cancer Research (AACR) at the Orange County Convention Center in Orlando, Florida on April 2-6, 2011.
OvaDx® is a sophisticated microarray-based blood test that measures the activation of the immune system in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. OvaDx® is being offered at $650 per test for research purposes only to advance the forefront of ovarian cancer research. OvaDx® can be used to analyze different tumor types and stages, the effectiveness of chemotherapies, biomarker profiles in breast cancer and other epithelial cancers, benign gynecological conditions, the efficacy of ovarian cancer drugs for treatment and prevention, and to benchmark existing tests including CA-125, OVA1®, and transvaginal ultrasound. Conference attendees are encouraged to visit Arrayit at AACR booth #1478 for more information.
Arrayit Chief Executive Officer Rene Schena states, "We are excited about the product launch of OvaDx® as a means of advancing the forefront of ovarian cancer research. This is an important milestone for Arrayit."
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2010 and Form 10-Q for the fiscal quarters ended June 30, 2010 and September 30, 2010.
Search News
